MX2017004322A - Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico. - Google Patents
Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico.Info
- Publication number
- MX2017004322A MX2017004322A MX2017004322A MX2017004322A MX2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A MX 2017004322 A MX2017004322 A MX 2017004322A
- Authority
- MX
- Mexico
- Prior art keywords
- aspirin
- metformin
- agent
- therapeutically effective
- pharmaceutical composition
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001138 acetylsalicylic acid Drugs 0.000 title abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003105 metformin Drugs 0.000 title abstract 2
- 239000002736 nonionic surfactant Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
- 229940076279 serotonin Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- WFZKRNIMSVDNBU-UHFFFAOYSA-N Creatinine sulfate mixture with serotonin Chemical compound [O-]S([O-])(=O)=O.C[NH+]1CC(=O)N=C1N.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 WFZKRNIMSVDNBU-UHFFFAOYSA-N 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 229960004329 metformin hydrochloride Drugs 0.000 abstract 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion se basa sobre el descubrimiento inesperado que una combinacion de determinados farmacos conocidos presenta efectos sinergisticos para tratar el sindrome metabolico y diversas otras enfermedades. En particular, la invencion comprende una composicion farmaceutica que consiste de: (1) una cantidad terapeuticamente efectiva de un primer agente que es metformina o una sal de la misma; (2) una cantidad terapeuticamente efectiva de un segundo agente que es aspirina; (3) una cantidad terapeuticamente efectiva de un tercer agente que es un complejo serotonina creatinina sulfato; (4) un agente tensioactivo no ionico; y (5) un disolvente que es un alcanol inferior. Una composicion preferida comprende clorhidrato de metformina, aspirina y complejo serotonina creatinina sulfato para el primer, segundo y tercer agente. La invencion comprende ademas procedimientos para el uso de estas composiciones para el tratamiento de sindrome metabolico, enfermedades hiperproliferativas incluyendo cancer, y otras enfermedades y condiciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462058150P | 2014-10-01 | 2014-10-01 | |
| PCT/US2015/053475 WO2016054365A1 (en) | 2014-10-01 | 2015-10-01 | Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004322A true MX2017004322A (es) | 2017-08-28 |
Family
ID=55631511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004322A MX2017004322A (es) | 2014-10-01 | 2015-10-01 | Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180228818A1 (es) |
| EP (1) | EP3200799A4 (es) |
| JP (1) | JP2017531035A (es) |
| KR (1) | KR20170057451A (es) |
| CN (1) | CN106999496A (es) |
| AR (1) | AR102147A1 (es) |
| AU (1) | AU2015328044A1 (es) |
| BR (1) | BR112017006778A2 (es) |
| CA (1) | CA2961660A1 (es) |
| MX (1) | MX2017004322A (es) |
| RU (1) | RU2017114350A (es) |
| TW (1) | TW201625232A (es) |
| WO (1) | WO2016054365A1 (es) |
| ZA (1) | ZA201702137B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840869A (zh) * | 2019-10-15 | 2020-02-28 | 四川大学华西第二医院 | 二甲双胍在子宫内膜异位症药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| ZA200609412B (en) * | 2004-05-17 | 2008-07-30 | Ares Trading Sa | Hydrogel interferon formulations |
| JP2010512230A (ja) * | 2006-12-11 | 2010-04-22 | プルーロームド インコーポレイテッド | 灌流臓器止血法 |
| ES2660173T3 (es) * | 2007-01-16 | 2018-03-21 | Ipintl, Llc | Nueva composición para el tratamiento del síndrome metabólico |
| EP2278999B1 (en) * | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| PL3111927T3 (pl) * | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy |
| AU2011234492B2 (en) * | 2010-04-01 | 2014-02-27 | Palette Life Sciences AB | Thermogelling anaesthetic compositions |
| WO2012135422A2 (en) * | 2011-04-01 | 2012-10-04 | University Of Florida Research Foundation, Inc. | Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics |
-
2015
- 2015-10-01 MX MX2017004322A patent/MX2017004322A/es unknown
- 2015-10-01 WO PCT/US2015/053475 patent/WO2016054365A1/en not_active Ceased
- 2015-10-01 CN CN201580053895.8A patent/CN106999496A/zh active Pending
- 2015-10-01 AU AU2015328044A patent/AU2015328044A1/en not_active Abandoned
- 2015-10-01 KR KR1020177011893A patent/KR20170057451A/ko not_active Withdrawn
- 2015-10-01 AR ARP150103170A patent/AR102147A1/es unknown
- 2015-10-01 CA CA2961660A patent/CA2961660A1/en not_active Abandoned
- 2015-10-01 TW TW104132456A patent/TW201625232A/zh unknown
- 2015-10-01 EP EP15845553.5A patent/EP3200799A4/en not_active Withdrawn
- 2015-10-01 US US15/516,152 patent/US20180228818A1/en not_active Abandoned
- 2015-10-01 RU RU2017114350A patent/RU2017114350A/ru not_active Application Discontinuation
- 2015-10-01 JP JP2017538159A patent/JP2017531035A/ja active Pending
- 2015-10-01 BR BR112017006778A patent/BR112017006778A2/pt not_active Application Discontinuation
-
2017
- 2017-03-27 ZA ZA2017/02137A patent/ZA201702137B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015328044A8 (en) | 2017-04-27 |
| AU2015328044A1 (en) | 2017-04-20 |
| AR102147A1 (es) | 2017-02-08 |
| CN106999496A (zh) | 2017-08-01 |
| RU2017114350A (ru) | 2018-11-05 |
| WO2016054365A1 (en) | 2016-04-07 |
| RU2017114350A3 (es) | 2019-04-22 |
| WO2016054365A8 (en) | 2017-04-13 |
| TW201625232A (zh) | 2016-07-16 |
| EP3200799A1 (en) | 2017-08-09 |
| CA2961660A1 (en) | 2016-04-07 |
| EP3200799A4 (en) | 2018-05-30 |
| ZA201702137B (en) | 2018-05-30 |
| JP2017531035A (ja) | 2017-10-19 |
| KR20170057451A (ko) | 2017-05-24 |
| BR112017006778A2 (pt) | 2018-01-09 |
| US20180228818A1 (en) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| JOP20230073A1 (ar) | بنزاميدات مستبدلة مع 3،1- ثيازول-2- يل | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| BR112016024020A8 (pt) | composição farmacêutica | |
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| MX2016014696A (es) | Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2017010277A (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| MY198553A (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
| MX2017004322A (es) | Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico. | |
| MX2016009226A (es) | Combinaciones farmaceuticas. |